Medicinal Chemistry News and Research

RSS

New LNP compositions that improve systemic delivery of RNAi therapeutics discovered

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today announced the publication of new data in the journal Nature Biotechnology by Alnylam scientists and collaborators from Tekmira Pharmaceuticals Corporation, AlCana Technologies, Inc., and The University of British Columbia (UBC). The new study employed a rational design approach for the discovery of novel lipids that can be incorporated into lipid nanoparticles (LNPs) for systemic delivery of RNAi therapeutics.

20 Jan 2010

EMBL-EBI hosts drug discovery database

ChEMBLdb, a vast online database of information on the properties and activities of drugs and drug-like small molecules and their targets, launches today with information on over half a million compounds. The data lie at the heart of translating information from the human genome into successful new drugs in the clinic.

19 Jan 2010

Pharma IQ to organize Anti-Infectives Summit in Philadelphia

Organized by Pharma IQ, a division of IQPC, the Anti-Infectives Summit will be held January 25-27, 2010 in Philadelphia, PA (www.anti-infectivesummit.com). This forum explores recent advances within anti-infective drug discovery and development, and is geared towards Chief Scientific Officers and Scientists working in microbiology, immunology, infectious diseases, medicinal chemistry and drug development.

From IQPC Ltd 10 Dec 2009

Galapagos' multiple milestone achievement triggers cash payment of EUR 10.2 million

Galapagos NV announced today achievement of multiple milestones under its alliance agreement in rheumatoid arthritis. The milestones trigger a cash payment of EUR 10.2 million to Galapagos.

3 Dec 2009

iThemba Pharmaceuticals and Pyxis Discovery sign a collaborative agreement

iThemba Pharmaceuticals' service division and Pyxis Discovery announced today that they have signed a collaborative agreement to jointly market both companies' services.

25 Nov 2009

Experimental drug to restore function of nerves damaged in spinal cord injuries shows promise

Researchers have shown how an experimental drug might restore the function of nerves damaged in spinal cord injuries by preventing short circuits caused when tiny "potassium channels" in the fibers are exposed.

20 Nov 2009

CDAS, Prestwick Chemical sign drug discovery research agreement

Caliper Life Sciences, Inc. (Nasdaq: CALP), a leading provider of tools and services for drug discovery and life sciences research, today announced a strategic partnership between the company's contract research organization, Caliper Discovery Alliances & Services (CDAS), and Prestwick Chemical (Strasbourg, France) to provide customized outsourced medicinal chemistry and in vitro and in vivo preclinical biology programs for drug discovery research.

19 Nov 2009

Locus Pharmaceuticals creates a new division, Ansaris

Locus Pharmaceuticals, a drug company that has developed its own internal and partnered pipeline, focusing on oncology, immunology, and inflammatory targets, today announced that in conjunction with a transformation to a drug discovery collaboration business model, it has created a new division, Ansaris, which will include most of its operations and personnel.

7 Nov 2009

SCYNEXIS receives payment as part of pharmaceutical discovery program with Merial

Merial Limited and SCYNEXIS, Inc. announced today that SCYNEXIS has earned a payment for meeting certain milestones in its multi-year research collaboration with Merial Limited, which began in 2005.

5 Nov 2009

Researchers to find better ways to manage chronic pain by treating neuroinflammation

Thanks to a two year, $974,024 NIH-funded ARRA (American Recovery and Reinvestment Act) grant, Saint Louis University and Southern Illinois University Edwardsville researchers are working to find better ways to manage chronic pain by treating neuroinflammation.

4 Nov 2009

Scientists develop technique to predict new target diseases for existing drugs

Scientists at the University of North Carolina at Chapel Hill School of Medicine and the University of California, San Francisco have developed and experimentally tested a technique to predict new target diseases for existing drugs.

4 Nov 2009

2009 Schering-Plough Excellence Award for WuXi PharmaTech

WuXi PharmaTech (Cayman) Inc., a leading pharmaceutical, biotechnology, and medical device research and development outsourcing company, with operations in China and the United States, today announced that it had received the 2009 Excellence Award from Schering-Plough.

30 Oct 2009

NIH awards DiscoveryBioMed grant to develop therapies for cystic fibrosis

DiscoveryBioMed, Inc. (DBM) today announced that it has been awarded a Phase 1 Small Business Innovation Research (SBIR) grant by the National Institutes of Health (NIH). The $308,000 grant will be used to advance certain small molecule drug discovery programs designed to correct the genetic mutation most common to cystic fibrosis (CF).

28 Oct 2009

Successful partnership between Mercury Therapeutics and CreaGen Biosciences highlighted

The recent licensing deal between Mercury Therapeutics and Debiopharm showcases the highly successful partnership between Mercury Therapeutics and CreaGen Biosciences, said CreaGen in a statement released today.

28 Oct 2009

Yissum Research Development signs long-term multi-project collaboration agreement with Roche

Yissum Research Development Company of the Hebrew University of Jerusalem Ltd., the technology transfer arm of the University, today announced that it has signed a long-term multi-project research and license collaboration agreement with Roche.

23 Oct 2009

U.S. Pharmacopeial fellowships awarded to 6 students

New research focused on the quality of key medicines and their use as well as increasingly popular botanicals is being sponsored by the U.S. Pharmacopeial (USP) Convention under its 2009� Fellowship Program.

21 Oct 2009

Ruthenium and Osmium compounds show high levels of activity against ovarian cancer

Drugs made using unusual metals could form an effective treatment against colon and ovarian cancer, including cancerous cells that have developed immunity to other drugs, according to research at the University of Warwick and the University of Leeds.

19 Oct 2009

Multi-million dollar cooperative agreement for SMA drug development program

Paratek Pharmaceuticals (Boston, MA) and Families of Spinal Muscular Atrophy (Elk Grove Village, IL) announced today that a jointly funded drug development program for Spinal Muscular Atrophy (SMA) has been awarded a multi-million dollar cooperative agreement from the National Institute of Neurological Disorders and Stroke (NINDS).

19 Oct 2009

TAXIS Pharmaceuticals, Rutgers and UMDNJ to develop and commercialize a novel antimicrobial technology

TAXIS Pharmaceuticals, Inc. (TAXIS), Rutgers, The State University of New Jersey, and the University of Medicine and Dentistry of New Jersey (UMDNJ) have entered into an exclusive licensing agreement for worldwide rights to develop and commercialize a novel antimicrobial technology addressing multidrug-resistant (MDR) bacterial infections.

14 Oct 2009

Compounds that bock nutrient-sensing receptor may impact obesity and diabetic conditions

According to new research from the Monell Center and the Mount Sinai School of Medicine, certain common herbicides and lipid-lowering fibrate drugs act in humans to block T1R3, a nutrient-sensing taste receptor also present in intestine and pancreas.

12 Oct 2009